Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The long-standing dream of using Artificial Intelligence (AI) to build an artificial brain has taken a significant step forward, as a team led by Professor Newton Howard from the University of Oxford has successfully prototyped a nanoscale, AI-powered, artificial brain in the form factor of a high-bandwidth neural implant.

Professor Newton Howard (pictured above and below) holding parts of the implant device

In collaboration with INTENT LTD, Qualcomm Corporation, Intel Corporation, Georgetown University and the Brain Sciences Foundation, Professor Howard’s Oxford Computational Neuroscience Lab in the Nuffield Department of Surgical Sciences has developed the proprietary algorithms and the optoelectronics required for the device. Rodents’ testing is on target to begin very soon.

This achievement caps over a decade of research by Professor Howard at MIT’s Synthetic Intelligence Lab and the University of Oxford, work that resulted in several issued US patents on the technologies and algorithms that power the device, the Fundamental Code Unit of the Brain (FCU), the Brain Code (BC) and the Biological Co-Processor (BCP) are the latest advanced foundations for anyeventual merger between biological intelligence and human intelligence. Ni2o (pronounced “Nitoo”) is the entity that Professor Howard licensed to further develop, market and promote these technologies.

Read more (Nuffield Department of Surgical Sciences website) 

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.